PACB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
40.6M
+4.0%
39.0M
+4.9%
37.2M
-16.7%
44.6M
+16.1%
38.4M
Cost of Revenue
27.1M
+2.7%
26.4M
+8.3%
24.3M
-13.3%
28.1M
+24.6%
22.5M
Gross Profit
13.5M
+6.6%
12.6M
-1.6%
12.8M
-22.5%
16.6M
+4.2%
15.9M
Operating Expenses
50.5M
-11.8%
57.2M
-14.5%
67.0M
+16.0%
57.8M
+5.4%
54.8M
R&D
20.2M
-12.2%
23.0M
+17.4%
19.6M
-14.3%
22.9M
+0.1%
22.8M
SG&A
29.4M
-11.9%
33.4M
+7.2%
31.2M
-8.5%
34.1M
+9.5%
31.1M
Operating Income
-37002000
+17.1%
-44610000
+17.6%
-54153000
-31.4%
-41197000
-6.0%
-38877000
EBITDA
-33006000
+19.0%
-40753000
-14.7%
-35533000
+5.1%
-37442000
-5.8%
-35396000
Net Income
-37846000
+15.4%
-44741000
-440.7%
-8275000
+79.5%
-40371000
-6.2%
-38000000
EPS (Basic)
$-0.12
+14.3%
$-0.14
-366.7%
$-0.03
+76.9%
$-0.13
+0.0%
$-0.13
EPS (Diluted)
$-0.12
+14.3%
$-0.14
-366.7%
$-0.03
+76.9%
$-0.13
+0.0%
$-0.13
Shares (Diluted)
311.2M
+0.2%
310.7M
+1.6%
305.8M
+1.3%
302.0M
+0.4%
300.8M
Pacific Biosciences of California (PACB) — Financials